Jani Meghna, Barton Anne, Ho Pauline
Arthritis Research UK Centre for Genetics and Genomics; Centre for Musculoskeletal Research, University of Manchester, Room 2.704, Stopford Building, Oxford Road, Manchester, M13 9PT, UK,
Curr Rheumatol Rep. 2015 Jul;17(7):44. doi: 10.1007/s11926-015-0518-z.
TNF-blocking agents, non-biological disease-modifying anti-rheumatic drugs (nbDMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed treatments in psoriatic arthritis. A large proportion of patients do not respond to these medications, although unfortunately clinically useful biomarkers that predict future response are currently lacking. Several candidate gene polymorphisms have been associated with responses to biologic therapies and nbDMARDs; however, replication and validation of these variants in large prospective psoriatic arthritis cohorts are required before translating these to clinical practice. In this review, we discuss the advances made in pharmacogenetics of treatment response in psoriatic arthritis to date, with focus on biologic therapies approved for use, nbDMARDs and NSAIDs, as well as outline emerging methodologies to obtain data that will help inform a future precision medicine approach in this condition.
肿瘤坏死因子阻断剂、非生物性改善病情抗风湿药（nbDMARDs）和非甾体抗炎药（NSAIDs）是银屑病关节炎常用的处方治疗药物。尽管目前不幸缺乏预测未来反应的临床有用生物标志物，但很大一部分患者对这些药物没有反应。几种候选基因多态性与生物治疗和nbDMARDs的反应有关；然而，在将这些变异应用于临床实践之前，需要在大型前瞻性银屑病关节炎队列中进行复制和验证。在这篇综述中，我们讨论了迄今为止银屑病关节炎治疗反应药物遗传学方面取得的进展，重点是已批准使用的生物治疗、nbDMARDs和NSAIDs，并概述了新兴的方法以获取有助于为这种疾病的未来精准医学方法提供信息的数据。
